Join our Sefia™ platform webinar series

Sefia™ cell therapy manufacturing platform: an end-to-end CAR T manufacturing solution.

"In cell therapy manufacturing, innovation and flexibility are key to ensuring that all eligible patients are getting the therapies they need as quickly as possible. As the global leader in cell therapy, Kite is proud to be on the forefront of cell therapy automation and to be part of a collaboration with Cytiva that developed the Sefia™ platform. Implementation of the Sefia™ platform enables us to increase efficiencies and produce CAR T cell therapies at a global scale."

 

- Chris McDonald, SVP, Global Head of Technical Operations, Kite

When it comes to cell therapy manufacturing, you’re not just in production. You’re crafting hope for millions awaiting these breakthrough treatments. And excelling on this path to commercial realization craves the support of a platform made specifically for cell therapy manufacturing. A platform that not only provides flexibility and easy integration, but also boosts productivity and automates key steps of your workflow.

Breakaway from asking “what if”… it’s time to get after "what’s next."

View Sefia™ platform brochure
Contact us to learn more
One of the main challenges of manufacturing autologous CAR T cell therapy is the cost. Open, manual operations are error- and contamination-prone. And if you’re thinking of scaling, the probability of these errors might just scale with you. But you can reduce the risk—while keeping flexibility—with closed and automated systems. Automation brings formerly discrete steps together, saving you time and money. Plus, by standardizing your process, you’re one step closer to meeting regulatory requirements—and to safely delivering your therapies to patients.